GHK-Cu, copper included

GHK, GHK-Cu and Copper Tripeptide-1

GHK is glycine-histidine-lysine, a chain of three amino acids. GHK-Cu is that chain bound to a copper(II) ion in a one-to-one complex. Copper Tripeptide-1 is its cosmetic ingredient name. The skin-regeneration review describes the peptide's matrix-building activity in cell studies (in vitro) and its natural occurrence.

The history begins with GHK, isolated from human plasma by Loren Pickart in 1973 as a factor that prompted aged liver tissue to make proteins more like younger tissue. The copper-bound form later became familiar in skin creams and serums. There is something pleasingly improbable to me about a plasma observation ending up on a bathroom ingredient list.

Copper coordination matters to the reported tissue-remodelling activity. Plain GHK and the copper complex can behave differently in cell studies. That makes the final two letters part of the experimental identity, even where “copper peptide” has become casual shorthand.

Copper measured across human skin

In the 2011 skin-layer experiment, the material was human skin studied outside the body. Copper delivered as GHK-Cu crossed dermatomed skin with a permeability coefficient of 2.43 ± 0.51 × 10⁻⁴ cm/h. Over 48 hours, 136.2 ± 17.5 µg/cm² of copper permeated, and 97 ± 6.6 µg/cm² was retained as a dermal depot.

These are copper quantities. I baulk at crediting intact-peptide delivery to a measurement of copper. “GHK-Cu penetrates” can sound as though the complex has been followed wherever a later claim needs it. The reported copper delivery and retention describe a narrower, useful experiment.

There is a second complication. The 2025 anti-wrinkle review identifies poor permeability through the outer skin barrier as a central problem for free GHK. Prepared skin layers and an intact skin barrier present different experimental conditions. I see no experimental justification for treating those conditions as interchangeable.

Skin and hair studies

The 2015 review of topical skin studies reports increased collagen production in 70% of treated women, compared with 50% for vitamin C and 40% for retinoic acid, alongside improvements in skin laxity, clarity, fine lines, wrinkle depth and density. The 2025 review repeats the procollagen comparison. Repetition in a later review gives the finding more readers; it supplies no new participants.

The six-month randomised hair trial in 45 men used a complex of 5-aminolevulinic acid and GHK peptide. Hair count increased by 52.6 and 71.5 at the two tested concentrations, versus 9.6 for placebo (p<0.05), with no adverse events in any group.

The combination earns the credit here. A trial that separates its ingredients would be needed to assign the gain to either ingredient alone. Calling it a GHK-Cu trial erases both the partner ingredient and the distinction between GHK and its copper complex.

Gene-expression database

The 2018 gene-data review reports GHK altering expression of about 31.2% of human genes at a threshold of 50% change or greater; 59% of affected genes increased and 41% decreased. The frequently circulated “around 4,000 genes” figure is an extrapolation, while the table at that threshold covers roughly 2,100 genes.

Much of the analysis comes from Connectivity Map, a gene-expression database. Protein-level confirmation in living tissue remains necessary. A demonstrated change in tissue would add more than a large gene count. The broader claims also face limited replication beyond a single investigator and colleagues.

Formulation and safety

The formulation review describes poor outer-skin permeability and efforts to improve delivery. Low-pH ascorbic acid and exfoliating acids can destabilise the copper complex. Once that binding breaks down, free copper can have pro-oxidant effects. The identity of the preparation can change before it reaches the skin.

Skincare communities report firmer-feeling skin, softer lines, hydration and reduced shedding. Irritation, stinging, dryness, breakouts and inconsistent pigment changes appear too. These are anecdotal observations, without the controls needed for clinical evidence. I do not interpret a brighter complexion reported online as evidence of systemic regeneration.

Topical use has a long cosmetic safety record. Injectable or other systemic GHK-Cu is unapproved and lacks validated human pharmacokinetic data. Prolonged systemic copper exposure raises a theoretical copper-balance concern, particularly with copper-handling disorders; published human copper-toxicity cases attributed to GHK-Cu are absent. The topical evidence cannot establish the safety of those systemic routes.

Cosmetic and sporting status

Topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK. GHK-Cu has no FDA-approved drug product for any indication; injectable and oral research-labelled forms continue to be sold, and a compounded preparation for clinical use has no FDA approval.

GHK-Cu was not listed on the 2024–2025 WADA Prohibited Lists. That historical listing status comes with a qualification: WADA's S0 catch-all category can cover non-approved pharmacological substances. The cosmetic ingredient name alone cannot settle a sporting eligibility question.